Health Canada Approves Stoboclo, Osenvelt Biosimilars to Prolia, Xgeva
September 19, 2025
Celltrion’s biosimilar portfolio continues to grow, expanding treatment options to reach more patients in Canada Celltrion announced that Health Canada has approved Stoboclo and Osenvelt (CT-P41), biosimilars